Bernard Coulie gives a deep dive into Pliant's IPF program, including news released this morning relating to patient PET scans.

Ian Mortimer gives the rationale for Kv7 in epilepsy and major depressive disorder, and explains why Xenon has chosen the NaV1.7 sodium...

Yuval Cohen describes why he believe his company's nectin-4 ADC has a next generation design, he covers the idea of integrin inhibition...

Brian Abrahams previews the conference, shares his take on biotech, and offers some themes to watch throughout the remainder of the year.

Thomas Renn, Head of Europe for Breakthrough Properties, introduces us to this state-of-the-art facility that will encompass 214,000...

Rahul Kakkar describes how PGI is being leveraged for both gene and cell therapy applications.

CEO Mike Severino describes the sickle cell data Tessera is presenting at #ASGCT2024, and highlights the company's gene writing platform...

Ring CEO Tuyen Ong introduces us to anelloviruses and describes the qualities that could make them compelling delivery vehicles. Animal...

Daniel de Boer describes how Axiomer harnesses the body's natural ADAR editing process to turn an A into an I, he covers NHP data for...

Head of research Robert Bell described the preclinical data in a Stargardt disease model that has led to an IND acceptance for this...

Founder & CEO Tao Fu walks us through the company's ATTOBODY platform and discusses programs targeting IL31 and IL31 x IL13.

Emily Walsh Martin covers regulatory comments from FDA's Peter Marks, scientific updates on prime and base editing, and more.

Jason Cole describes how Gene Coding can deliver large sequences to the genome without viral vectors or RNA guides, and describes how...

TJ Cradick gives us a preview of which abstracts and technologies to watch this year, including the latest in gene editing methods and...

An early adopter and researcher of AI, Noam Auslander shares her opinion of the benefits of AI but also guardrails that should be...

He explains how machine learning has allowed bit.bio to model which transcription factor combinations are needed to create a desired cell...

Jack O'Meara describes Ochre's unique preclinical testing strategy as it develops siRNA drugs for liver diseases, and he touches on a...

CIC Partner Michael Anstey describes the firm's history and investment approach, lists some current investments, and offers advice for...

Dr. Jhoti discusses the history of Astex, shows us a state-of-the-art cryo-EM microscope they have on site, and highlights the three...

Kathryn Chapman has held many roles in town and is an expert on everything Cambridge's life sciences ecosystem has to offer.